Systematic genetic testing for personalised ovarian cancer therapy (SIGNPOsT)
Not Applicable
- Conditions
- Epithelial ovarian cancerCancer
- Registration Number
- ISRCTN16988857
- Lead Sponsor
- Queen Mary University of London
- Brief Summary
2023 Other publications in https://pubmed.ncbi.nlm.nih.gov/37752678/ Cohort study set within the recruitment to SIGNPOST (added 27/09/2023)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- Female
- Target Recruitment
- 280
Inclusion Criteria
1. Aged over 18 years
2. Histological diagnosis of high-grade non-mucinous epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer
Exclusion Criteria
1. Women with non-epithelial ovarian cancer
2. Women with low grade or mucinous epithelial ovarian cancer
3. Unable to consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method